Published in Proc Natl Acad Sci U S A on August 28, 2007
Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins. Nat Chem Biol (2010) 1.62
Protein homeostasis in models of aging and age-related conformational disease. Adv Exp Med Biol (2010) 1.48
ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum Mol Genet (2010) 1.32
Probing mechanisms that underlie human neurodegenerative diseases in Drosophila. Annu Rev Genet (2012) 1.21
Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem (2009) 1.12
Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activity. Curr Neuropharmacol (2009) 1.04
Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington's disease. Cell Death Dis (2011) 1.00
Socially responsive effects of brain oxidative metabolism on aggression. Proc Natl Acad Sci U S A (2014) 0.97
Meclizine is neuroprotective in models of Huntington's disease. Hum Mol Genet (2010) 0.92
Identifying druggable disease-modifying gene products. Curr Opin Chem Biol (2009) 0.91
Animal models of polyglutamine diseases and therapeutic approaches. J Biol Chem (2008) 0.90
MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition. J Neurosci (2013) 0.90
CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's disease. Hum Mol Genet (2010) 0.86
High throughput screening for neurodegeneration and complex disease phenotypes. Comb Chem High Throughput Screen (2008) 0.84
Mutant huntingtin alters cell fate in response to microtubule depolymerization via the GEF-H1-RhoA-ERK pathway. J Biol Chem (2010) 0.84
A novel target for Huntington's disease: ERK at the crossroads of signaling. The ERK signaling pathway is implicated in Huntington's disease and its upregulation ameliorates pathology. Bioessays (2012) 0.81
Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases. Chem Cent J (2015) 0.77
Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease. J Huntingtons Dis (2012) 0.76
Connectivity mapping uncovers small molecules that modulate neurodegeneration in Huntington's disease models. J Mol Med (Berl) (2015) 0.75
The extracellular signal-regulated kinase 1/2 pathway in neurological diseases: A potential therapeutic target (Review). Int J Mol Med (2017) 0.75
Enhanced neuronal glucose transporter expression reveals metabolic choice in a HD Drosophila model. PLoS One (2015) 0.75
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem (1994) 14.36
Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem (1998) 13.93
Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science (1989) 9.71
Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature (2001) 6.76
Rates of behavior and aging specified by mitochondrial function during development. Science (2002) 6.28
Mitochondria: releasing power for life and unleashing the machineries of death. Cell (2003) 5.07
Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell (2006) 4.53
Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci (1999) 4.27
Mitochondrial retrograde signaling. Annu Rev Genet (2006) 3.75
Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron (1998) 3.72
Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci (2003) 3.67
A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron (1999) 3.50
Isolation of human cell lines lacking mitochondrial DNA. Methods Enzymol (1996) 2.70
Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron (2002) 2.67
A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol (2005) 2.64
The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell (2002) 2.56
Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A (2003) 2.35
Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma. Nat Med (2003) 2.35
Neurotoxicity of sodium fluoride in rats. Neurotoxicol Teratol (1995) 2.23
Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci (2000) 1.92
IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta (2006) 1.88
Higher sedentary energy expenditure in patients with Huntington's disease. Ann Neurol (2000) 1.86
Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal (2006) 1.82
Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc Natl Acad Sci U S A (2007) 1.57
Mitochondrial uncoupling as a target for drug development for the treatment of obesity. Obes Rev (2001) 1.54
Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol (1999) 1.50
Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity. Proc Natl Acad Sci U S A (2002) 1.46
Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet (2005) 1.42
Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol (2001) 1.27
Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci (2005) 1.27
Energy supply and the shape of death in neurons and lymphoid cells. Cell Death Differ (1997) 1.27
Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans. PLoS One (2007) 1.25
Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain (2006) 1.20
Mitochondria make a come back. Adv Drug Deliv Rev (2001) 1.20
Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. Hum Mol Genet (2005) 1.08
Caspase-independent cell death induced by anti-CD2 or staurosporine in activated human peripheral T lymphocytes. J Immunol (1998) 1.07
Mechanism of inhibition of mitochondrial adenosine triphosphatase by dicyclohexylcarbodiimide and oligomycin: relationship to ATP synthesis. Proc Natl Acad Sci U S A (1985) 1.05
Selective inhibitors of death in mutant huntingtin cells. Nat Chem Biol (2006) 0.99
Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol Cell Biochem (2005) 0.99
Energy balance in early-stage Huntington disease. Am J Clin Nutr (2005) 0.97
Bioenergetics in Huntington's disease. Ann N Y Acad Sci (1999) 0.95
The effects of dietary restriction on mitochondrial dysfunction in aging. Ann N Y Acad Sci (1998) 0.94
ATP depletion inhibits glucocorticoid-induced thymocyte apoptosis. Biochem J (1997) 0.93
Caspases in Huntington's disease. Neuroscientist (2001) 0.92
Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance. Lancet Oncol (2005) 0.91
Expression of full-length polyglutamine-expanded Huntingtin disrupts growth factor receptor signaling in rat pheochromocytoma (PC12) cells. J Biol Chem (2001) 0.89
Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity. J Neurochem (2000) 0.82
Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors. Bioorg Med Chem Lett (2004) 0.82
Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease. J Neurol (2006) 0.81
Effect of sodium fluoride on glycolysis in human erythrocytes and Ehrlich ascites tumour cells in vitro. Acta Biochim Pol (1976) 0.81
Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis. Arch Intern Med (2001) 0.81
Rotenone and pyruvate prevent the tert-butylhydroperoxide-induced necrosis of U937 cells and allow them to proliferate. FEBS Lett (1999) 0.80
Effect of hypoenergetic feeding on muscle oxidative phosphorylation and mitochondrial complex I-IV activities in rats. Am J Clin Nutr (2002) 0.79
Neurodegenerative conditions associated with ageing: a molecular interplay? Mech Ageing Dev (2005) 0.77
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell (2012) 6.31
Conserved pathways within bacteria and yeast as revealed by global protein network alignment. Proc Natl Acad Sci U S A (2003) 4.68
Multicomponent therapeutics for networked systems. Nat Rev Drug Discov (2005) 3.99
Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A (2003) 3.86
Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet (2004) 3.84
An ARC/Mediator subunit required for SREBP control of cholesterol and lipid homeostasis. Nature (2006) 3.23
Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell (2003) 3.23
RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature (2007) 3.21
PathBLAST: a tool for alignment of protein interaction networks. Nucleic Acids Res (2004) 3.20
Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol (2010) 3.01
A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell (2011) 2.75
Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell (2009) 2.57
Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev (2010) 2.55
Optical interrogation of neural circuits in Caenorhabditis elegans. Nat Methods (2009) 2.51
Chemical combination effects predict connectivity in biological systems. Mol Syst Biol (2007) 2.42
An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell (2013) 2.30
Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol (2008) 2.04
Feeding status and serotonin rapidly and reversibly modulate a Caenorhabditis elegans chemosensory circuit. Proc Natl Acad Sci U S A (2004) 2.04
Combination chemical genetics. Nat Chem Biol (2008) 1.98
Local RNA translation at the synapse and in disease. J Neurosci (2011) 1.83
Modeling spinal muscular atrophy in Drosophila. PLoS One (2008) 1.71
C. elegans Notch signaling regulates adult chemosensory response and larval molting quiescence. Curr Biol (2011) 1.69
Towards patient-based cancer therapeutics. Nat Biotechnol (2010) 1.63
Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins. Nat Chem Biol (2010) 1.62
Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J Neurosci (2006) 1.51
Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc (2014) 1.49
Microarrays of small molecules embedded in biodegradable polymers for use in mammalian cell-based screens. Proc Natl Acad Sci U S A (2004) 1.48
Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity. Proc Natl Acad Sci U S A (2002) 1.46
Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem Biol (2004) 1.45
Modulatory profiling identifies mechanisms of small molecule-induced cell death. Proc Natl Acad Sci U S A (2011) 1.45
Breath malodor reduction with use of a stannous-containing sodium fluoride dentifrice: a meta-analysis of four randomized and controlled clinical trials. Am J Dent (2010) 1.44
Autophagy genes protect against disease caused by polyglutamine expansion proteins in Caenorhabditis elegans. Autophagy (2007) 1.40
C. elegans G protein regulator RGS-3 controls sensitivity to sensory stimuli. Neuron (2007) 1.36
Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans. PLoS One (2007) 1.25
Biological mechanism profiling using an annotated compound library. Chem Biol (2003) 1.23
OSM-11 facilitates LIN-12 Notch signaling during Caenorhabditis elegans vulval development. PLoS Biol (2008) 1.22
Motoneurons dedicated to either forward or backward locomotion in the nematode Caenorhabditis elegans. J Neurosci (2010) 1.20
G protein-coupled receptor kinase function is essential for chemosensation in C. elegans. Neuron (2004) 1.19
Protein folding drives disulfide formation. Cell (2012) 1.18
Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. Genome Biol (2008) 1.15
A flexible data analysis tool for chemical genetic screens. Chem Biol (2004) 1.15
Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum Mol Genet (2006) 1.14
Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett (2011) 1.10
Conserved genes act as modifiers of invertebrate SMN loss of function defects. PLoS Genet (2010) 1.07
Detecting spatial patterns in biological array experiments. J Biomol Screen (2003) 1.06
Functional model of metabolite gating by human voltage-dependent anion channel 2. Biochemistry (2011) 1.00
Identification of inhibitors of ribozyme self-cleavage in mammalian cells via high-throughput screening of chemical libraries. RNA (2006) 0.99
Selective inhibitors of death in mutant huntingtin cells. Nat Chem Biol (2006) 0.99
Identification of Simple Compounds with Microtubule-Binding Activity That Inhibit Cancer Cell Growth with High Potency. ACS Med Chem Lett (2011) 0.98
Neurodegenerative disorders: insights from the nematode Caenorhabditis elegans. Neurobiol Dis (2010) 0.97
Advances in chemical genetics. Annu Rev Genomics Hum Genet (2005) 0.97
Using small molecules to overcome drug resistance induced by a viral oncogene. Cancer Cell (2006) 0.96
Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Cancer Discov (2011) 0.94
Deep conservation of genes required for both Drosphila melanogaster and Caenorhabditis elegans sleep includes a role for dopaminergic signaling. Sleep (2014) 0.93
Design and synthesis of Pictet-Spengler condensation products that exhibit oncogenic-RAS synthetic lethality and induce non-apoptotic cell death. Bioorg Med Chem Lett (2012) 0.92
Gene expression-based screening for inhibitors of PDGFR signaling. Genome Biol (2008) 0.92
lin-12 Notch functions in the adult nervous system of C. elegans. BMC Neurosci (2005) 0.92
Identifying druggable disease-modifying gene products. Curr Opin Chem Biol (2009) 0.91
Treatment of proximal interphalangeal dorsal fracture-dislocation injuries with dynamic external fixation: a pins and rubber band system. J Hand Surg Am (2007) 0.91
Eliminating membrane depolarization caused by the Alzheimer peptide Abeta(1-42, aggr.). Biochem Biophys Res Commun (2002) 0.89
Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. ACS Chem Biol (2015) 0.89
The E3 ubiquitin ligase mind bomb 1 ubiquitinates and promotes the degradation of survival of motor neuron protein. Mol Biol Cell (2013) 0.88
Genetic circuitry of Survival motor neuron, the gene underlying spinal muscular atrophy. Proc Natl Acad Sci U S A (2013) 0.86
Dietary restriction involves NAD⁺ -dependent mechanisms and a shift toward oxidative metabolism. Aging Cell (2014) 0.86
Global analysis of large-scale chemical and biological experiments. Curr Opin Drug Discov Devel (2002) 0.85
Determinants of place of death for recipients of home-based palliative care. J Palliat Care (2010) 0.84
Therapeutic approaches to preventing cell death in Huntington disease. Prog Neurobiol (2012) 0.84
High throughput screening for neurodegeneration and complex disease phenotypes. Comb Chem High Throughput Screen (2008) 0.84
Mutant huntingtin alters cell fate in response to microtubule depolymerization via the GEF-H1-RhoA-ERK pathway. J Biol Chem (2010) 0.84
Restoring functions of tumor suppressors with small molecules. Cancer Cell (2003) 0.83
Chemical genetic approaches to probing cell death. Curr Opin Chem Biol (2006) 0.83
The development of an intraoperative plantar pressure assessment device. Foot Ankle Int (2009) 0.82
Caenorhabditis elegans as a model system for triplet repeat diseases. Methods Mol Biol (2004) 0.82
Relative magnitude of vascular reactivity in the major arterioles of the retina. Microvasc Res (2011) 0.81
Chemical genetics and orphan genetic diseases. Chem Biol (2005) 0.81
A novel role for jun N-terminal kinase signaling in olfactory sensory neuronal death. Mol Cell Neurosci (2008) 0.80
Assaying mechanosensation. WormBook (2014) 0.80
The neuroprotective drug riluzole acts via small conductance Ca2+-activated K+ channels to ameliorate defects in spinal muscular atrophy models. J Neurosci (2013) 0.79
Identification of a small molecule that induces ATG5-and-cathepsin-l-dependent cell death and modulates polyglutamine toxicity. Exp Cell Res (2013) 0.78
Arylazanylpyrazolone derivatives as inhibitors of mutant superoxide dismutase 1 dependent protein aggregation for the treatment of amyotrophic lateral sclerosis. J Med Chem (2013) 0.78
Clinical evaluation of the fast onset and sustained sensitivity relief of a 0.454% stannous fluoride dentifrice compared to an 8.0% arginine-calcium carbonate-sodium monofluorophosphate dentifrice. Am J Dent (2011) 0.77
Development of an anatomical wrist joint coordinate system to quantify motion during functional tasks. J Appl Biomech (2014) 0.77
Comparative bioavailability and antimicrobial activity of cetylpyridinium chloride mouthrinses in vitro and in vivo. Am J Dent (2014) 0.77
Drug discovery: engineering drug combinations. Nat Chem Biol (2010) 0.77
Chemical biology: renewing embryonic stem cells. Nature (2006) 0.77
A mammalian cell-based assay for screening inhibitors of RNA cleavage. Methods Mol Biol (2009) 0.77
Rapid desensitizing efficacy of a stannous-containing sodium fluoride dentifrice. J Clin Dent (2011) 0.77
Tricuspid Regurgitation, the Forgotten Valvular Lesion-A Contemporary Review of Etiology, Prevalence, and Management Options. Rev Cardiovasc Med (2015) 0.76
Small molecule screen reveals regulation of survival motor neuron protein abundance by Ras proteins. ACS Chem Biol (2013) 0.76
Outcomes of biventricular mechanical support patients discharged to home to await heart transplantation. J Cardiovasc Nurs (2015) 0.76
Do C. elegans sleep? A closer look. Sleep (2013) 0.76
Enzyme annotation with chemical tools. Chem Biol (2006) 0.75
The biological magic behind the bullets. Nat Biotechnol (2004) 0.75
Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with everolimus-eluting stents. J Invasive Cardiol (2012) 0.75